Ampio Pharmaceuticals Inc (AMPE) Short Interest Update
Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 8,894,839 shares, a growth of 10.8% from the November 30th total of 8,028,174 shares. Currently, 12.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,458,731 shares, the short-interest ratio is currently 3.6 days.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) opened at $4.07 on Monday. Ampio Pharmaceuticals has a 52-week low of $0.38 and a 52-week high of $4.95. The stock has a market capitalization of $268.77, a P/E ratio of -20.35 and a beta of 0.58.
Separately, ValuEngine upgraded Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 11th.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/12/31/ampio-pharmaceuticals-inc-ampe-short-interest-update.html.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.